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Human dopamine (DA) transporter (hDAT) regulates dopaminergic signaling in the central 
nervous system by maintaining the synaptic concentration of DA at physiological levels, 
upon reuptake of DA into presynaptic terminals. DA translocation involves the co-transport 
of two sodium ions and the channeling of a chloride ion, and it is achieved via alternating 
access between outward-facing (OF) and inward-facing states of DAT. hDAT is a target for 
addictive drugs, such as cocaine, amphetamine (AMPH), and therapeutic antidepressants. 
Our recent quantitative systems pharmacology study suggested that orphenadrine (ORPH), an 
anticholinergic agent and anti-Parkinson drug, might be repurposable as a DAT drug. Previous 
studies have shown that DAT-substrates like AMPH or -blockers like cocaine modulate the 
function of DAT in different ways. However, the molecular mechanisms of modulation remained 
elusive due to the lack of structural data on DAT. The newly resolved DAT structure from 
Drosophila melanogaster opens the way to a deeper understanding of the mechanism and 
time evolution of DAT–drug/ligand interactions. Using a combination of homology modeling, 
docking analysis, molecular dynamics simulations, and molecular biology experiments, we 
performed a comparative study of the binding properties of DA, AMPH, ORPH, and cocaine 
and their modulation of hDAT function. Simulations demonstrate that binding DA or AMPH 
drives a structural transition toward a functional form predisposed to translocate the ligand. In 
contrast, ORPH appears to inhibit DAT function by arresting it in the OF open conformation. 
The analysis shows that cocaine and ORPH competitively bind DAT, with the binding pose 
and affinity dependent on the conformational state of DAT. Further assays show that the effect 
of ORPH on DAT uptake and endocytosis is comparable to that of cocaine.
Keywords: human dopamine transporter, repurposable drugs, amphetamine, orphenadrine cocaine, drug 
modulation mechanism
introduction
The dopamine (DA) transporter (DAT) belongs to the SLC6 family of neurotransmitter:sodium 
symporters (NSSs, or solute carrier 6), structurally and functionally similar to transporters of 
serotonin (SERT) and norepinephrine (NET). DAT regulates the termination of dopaminergic 
signaling by reuptake of DA from synaptic clefts, assisted by the co-transport of Na+ ions down their 
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electrochemical gradient and accompanied by Cl- channeling. It is 
generally accepted that the NSS family functions through alternat-
ing access between outward-facing (OF) and inward-facing (IF) 
states (1). Uptake of substrate from the extracellular (EC) region 
takes place in the OF state and its release to the intracellular (IC) 
side, in the IF state. The OF and IF states may be open or closed 
depending on the local conformation of their respective EC- or 
IC-gating residues.
Dysfunction of hDAT has been implicated in many neuro-
logical diseases or psychiatric disorders [for reviews, see Ref. 
(2–4)], such as depression, Parkinson’s disease (PD) (5), epilepsy, 
autism (6), attention-deficit hyperactivity disorder (ADHD), 
obsessive–compulsive disorder, and Alzheimer’s disease. DAT is 
a target for addictive drugs and psychostimulants, such as cocaine 
and amphetamine (AMPH), and for therapeutic antidepressants. 
These modulate DAT structure and function through different 
mechanisms [review see Ref. (2)]. Cocaine acts as a DAT blocker 
by directly binding DAT and preventing the translocation of DA. 
AMPH, on the other hand, competes with DA and triggers the 
reverse transport (efflux) of DA from the cell interior to the synapse. 
Javitch, Galli, and Gnegy proposed that phosphorylation of one or 
more serines at the N-terminal end of DAT is essential for AMPH-
induced DA efflux (7). AMPH also has indirect effects: it reverses 
the action of vesicular monoamine transporter 2 (VMAT2) (8) to 
stimulate the release of neurotransmitters (including serotonin, 
epinephrine in addition to DA) from synaptic vesicles to the 
presynaptic cell interior, and activates the trace amino-associated 
receptor 1 (TAAR1) (9) to trigger the efflux of DA by DAT. All 
these actions lead to increased synaptic DA levels, although the 
detailed mechanisms by which these effects take place remain 
unknown. Furthermore, these drugs may impact the trafficking 
of DATs [reviewed in Ref. (10)].
Human dopamine transporter has the same fold as leucine 
transporter (LeuT). LeuT has long served as a prototype for 
exploring NSS structure and function, being the first member 
of the NSS family, which has been structurally resolved at the 
atomic level (11). Despite its low (~20%) sequence identity to 
eukaryotic NSSs, the resolved LeuT structure (from the eubac-
teria homologue Aqufex aeolicus) provided valuable insights into 
the structural aspects of transport by eukaryotic NSS family 
members (12–20), mainly because its 3D architecture, LeuT fold, 
is shared by family members. The LeuT fold consists of 12 trans-
membrane (TM) helices organized in two pseudo-symmetric 
inverted repeats (11, 21): TM1–TM5 and TM6–TM10. TM1 and 
TM6 are broken near the substrate/ion-binding site. To date, 
LeuT has been crystallographically resolved in four conforma-
tions: substrate-bound OF closed (11) (shortly designated as 
OFc*, with the asterisk indicating substrate/ion-bound state), 
inhibitor-bound OF open (OFo*) (22), substrate-free OF open 
(OFo), and IF open (IFo) (23) conformations. Insights from 
structural data have been complemented by computational 
studies [e.g., molecular dynamics (MD) simulations] toward 
understanding the mechanism of transport by NSS family 
members (14, 16, 18–20, 24–32). In particular, the N-terminal 
segment of LeuT has been shown to play a key role in regulating 
the opening/closure of the IC gate and in resuming the transport 
cycle (24).
While structural models based on LeuT helped us make 
inferences on DAT structure and interactions, DAT differs 
from LeuT in terms of its sequence (sequence identity of 22%), 
detailed structure, as well as function. The recent resolution of 
the first eukaryotic DAT structure (33), dDAT, from Drosophila 
melanogaster, has opened the way to a structure-based explora-
tion of DAT mechanism of function. dDAT has more than 50% 
sequence identity with hDAT (33). Moreover, the orientation 
of the TM12 helix in the dDAT crystal structure differs signifi-
cantly from that in LeuT (33); and part of the DAT C-terminus 
is resolved for the first time. Although the dDAT structure 
lacks data on a 43-residue portion of the EC-exposed EL2 loop, 
which has been deleted (Δ164-206) in the crystal structure 
(33), it still serves as an excellent template for investigating 
the structure and dynamics of hDAT. The fact that the dDAT 
structure is resolved in the presence of nortriptyline (33), an 
antidepressant that inhibits transport, further helps in explor-
ing the structural and dynamic bases of the actions of DAT 
substrates/blockers.
In addition to structure-based studies, there has been a 
surge in recent years in the number of quantitative systems 
pharmacology (QSP) approaches that exploit existing knowledge 
of protein–drug interactions. QSP approaches help reduce wet 
lab work, assist in selecting lead compounds, assessing side 
effects (34), and identifying repurposable drugs (35, 36). Most 
psychotropic drugs (e.g., clozapine, tricyclic antidepressants 
like amitriptyline) owe their efficacy to multiple interactions 
(37). QSP methods may thus be particularly useful in designing 
transporter blockers, which still is the most common strategy 
for antidepressant therapy in spite of known side effects (33, 
38). We recently developed a probabilistic matrix factorization 
(PMF)-based method (39) that uses the known FDA-approved 
drug–target interactions as input to predict possible, but yet 
undisclosed interactions (40, 41).
In this study, we present an integrated computational and 
experimental study to elucidate the mechanism of interaction of 
drugs with DAT and their pharmacological implications. First, 
we combine the output from PMF computations with structural 
similarity analyses (42, 43), so as to extract potentially repurpos-
able drugs (35, 36) for hDAT. The analysis highlights the potential 
significance of orphenadrine (ORPH), an inhibitor of NET 
reuptake (44), as a repurposable hDAT-inhibitor. A comparative 
MD study of ORPH, DA, and AMPH reveals the time-resolved 
mechanisms of binding and associated conformational changes; 
while DA uptake and endocytosis assays reveal the consequences 
on DAT function. Overall, our study suggests that ORPH inhibits 
DAT, like cocaine; while AMPH and DA share similar mechanisms 
of action and tend to stimulate the predisposition of DAT to 
substrate transport.
Materials and Methods
computational Material and Methods
Combined PMF and 3D Structural Similarity Filtering of 
Known Drugs
Details of the PMF-based method for identifying repurposable 
drugs, side effects, and drug–drug or target–target similarities 
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are described in our previous work and in the tutorial of the web 
interface that we developed to facilitate the use of the PMF-based 
package for QSP (39, 41). In a nutshell, the PMF uses as input a 
dataset of drug–target associations [e.g., those listed in DrugBank 
(45)]. The association profiles/patterns for each drug (or target) 
across all targets (or drugs) are used to make new inferences 
about potential drug–target interactions. In the present applica-
tion, the repurposable drugs predicted by PMF for DAT as well 
as those known to bind/interact with DAT were clustered using 
agglomerative hierarchical cluster trees (Matlab). Three distance 
metrics (Euclidian, cosine and City-block/Mahalanobis) were used 
to extract the associations that were robustly predicted regardless 
of the metric. Dendogram enrichment technique was adopted to 
identify those clusters enriched in known drugs. The 3D structural 
similarities between drugs were examined using OpenEye1 toolkits 
OMEGA (42) and Shape (43).
Homology Modeling of hDAT
Homology models for hDAT (Q58 to E598) in the OFo state were 
constructed using MODELLER (46) based on the dDAT crystal 
structure (33). The alignment of the two sequences was generated 
using Uniprot2. To model the human counterpart of the EL2 loop 
segment that was deleted in the crystal dDAT, we first considered 
two closely interacting cysteines (C148 and C157) at the end of the 
EL2 loop. The close positioning of these highly conserved cysteines 
in the resolved structure suggests that they formed a disulfide simi-
lar to that proposed for eukaryotic NSS family members (16, 47). 
Thus a disulfide bridge between their hDAT counterparts, C180 
and C189, was adopted as a structural constraint in our homology 
modeling. One hundred homology models were constructed and 
that with the best (lowest MODELLER objective function) score 
was selected for further refinement and simulations (Figure 1). 
The quality of the modeled EL2 loop was assessed based on three 
criteria (16): (i) the three N-glycosylation sites N181, N188, and 
N205 were required to be exposed to the EC medium; (ii) C180 
and C189 would form a disulfide bond; (iii) H193 and D206 (in 
EL2) would be in close proximity to H375 and E396 (in EL4) since 
a zinc ion is known to be coordinated by these four residues. The 
modeled EL2 loop adopted as the initial conformation satisfied 
all these three criteria (see Figure 1B). We note that during the 
course of simulations EL2 was highly flexible and disordered, 
and the putative Zn2+ binding site was transiently stabilized upon 
binding cations.
Docking Simulations
Docking simulations were performed with AutoDock (48) and 
Smina (49) using the energy-minimized hDAT OFo homology 
model as well as OFo conformers sampled during MD simula-
tions. For each protein model/conformer, we performed our 
docking analysis under two conditions: in the presence of the 
sodium and chloride ions bound to hDAT and in their absence. 
Docking parameters for sodium and chloride were taken from the 
parameter library in AutoDock and fine-tuned to reproduce the 
1 http://www.eyesopen.com
2 http://www.uniprot.org
binding pose of the antidepressant resolved in the crystal dDAT 
structure (33). The radius, vdW well depth, and effective charge 
were taken as 1.3 Å, 0.137 kcal/mol, and 1.0e, respectively, for Na+ 
ions; and 4.09 Å, 0.031 kcal/mol, and -1.0e, respectively, for Cl- ion. 
For each system, 100 independent docking runs were performed 
using a Lamarckian genetic algorithm with default parameters 
(48), with the maximal number of energy evaluations set to 
2.5 × 107. The simulation box was divided into 112 × 112 × 126 
grids with a spacing of 0.6 Å. The binding energy was estimated 
from the weighted average from multiple binding poses of the 
small molecule at a given site.
Parameterizations of Substrate/Drugs
Dopamine, AMPH, ORPH, or cocaine all carry +1 charge. 
Force field parameters for these small molecules were obtained 
from the CHARMM General Force Field (CGenFF version 
0.9.7.1 beta) for drug-like molecules (50), using the web server 
ParamChem. The penalties associated with the use of the listed 
parameters for DA, AMPH, and ORPH were verified to be within 
acceptable limits (<10) such that no further refinement was 
required (51). In contrast, those predicted by ParamChem for 
cocaine had high penalties (>50). Instead, we used antechamber 
Figure 1 | Molecular dynamics (MD) setup for simulating the 
interaction of DaT with dopamine (Da), orphenadrine (OrPh), and 
amphetamine (aMPh). (a) A representative hDAT conformation observed 
in simulations. The hDAT OFo structure (orange) constructed using homology 
modeling based on dDAT [PDB: 4M48 (33)] is embedded into a POPC lipid 
bilayer (green). The substrate DA (purple) is initially placed in the most 
favorable binding site indicated by docking simulations. Water molecules are 
displayed in red lines. The cyan and yellow spheres represent the Cl− and two 
Na+ ions resolved in the crystal structure. Two oppositely charged pairs of 
residues, R85-D476 (extracellular, EC) and R60-D436 (intracellular. IC), 
function as the putative EC and IC gates (counterparts of R30-D404 and 
R5-D369 in LeuT). (B) A closeup view of the modeled EL2 loop. The region 
(S190 to P212) whose homologous counterpart was unresolved in the crystal 
dDAT structure is shown in green. The labeled residues shown in stick 
representation were used as probes for model assessment (see the text).
June 2015 | Volume 6 | Article 1344
Cheng et al. Drug modulation of hDAT
Frontiers in Neurology | www.frontiersin.org
tool (52)  implemented in AMBER (53) and MD simulations 
of cocaine binding were performed using AMBER (see 
Supplementary material).
MD Simulations
Unless otherwise stated explicitly, all MD simulations were 
performed using the NAMD2 software (54), adopting previ-
ous simulation protocol (25). MD simulation systems were set 
up using VMD (55). Two sodium ions, one chloride, and one 
cholesterol molecule resolved in the crystal structure (33) were 
included in the initial structure. The TM domain of hDAT OFo 
was inserted into the center of pre-equilibrated 1-palmitoyl-
2-oleoylphosphatidyl choline (POPC) lipid bilayer, following 
previous approach (25). Fully equilibrated TIP3 waters were 
added to form a box of 104.6 × 104.6 × 150 Å3. Na+ and Cl− ions 
corresponding to a 0.15 M solution were added to neutralize the 
system. The simulation box contained 1 hDAT, 196 POPC mol-
ecules, 88 Cl− ions, 83 Na+ ions, 2 Zn2+, 4 cholesterol molecules, 
and about 29,100 water molecules, summing up to a total of over 
140,000 atoms. One control system without drug/substrate and 
three additional systems in the presence of DA, AMPH, and 
ORPH were constructed. The ligand/drug were bound to the most 
favorable binding site identified by AutoDock, which is located in 
the vicinity of the primary substrate-binding site S1 (see Figure 1). 
To explore the existence of a possible secondary binding site S2 
(56), an additional DA molecule was placed in the EC solution 
near the EC-facing vestibule of DAT.
CHARMM36 force field with CMAP corrections was used for 
hDAT, water, and lipid molecules (57–59). Prior to productive 
runs, each system was energy-minimized for 50,000 steps, followed 
by 0.5 ns constant volume and temperature (T = 310 K; NVT) 
simulations and a subsequent 4 ns Nosé–Hoover (60, 61) constant 
pressure and temperature (1 bar, 310 K; NPT) simulation, during 
which the protein was fixed and constraints on the POPC head 
groups were gradually released. Subsequently, the constraints 
on the protein backbone were reduced from 10 to 0  kcal/mol 
within 3 ns. Finally, the unconstrained protein was subjected to 
NPT simulations. For each of the four simulated systems, two 
independent MD runs of 100 ns were performed, designated as 
apo-1 and -2, DA-bound-1 and -2, AMPH-bound-1 and -2, and 
ORPH-bound-1 and -2.
Trajectory Analysis
VMD (55) was used to analyze the root mean square deviation 
(RMSD) of hDAT from its initial conformation, the root mean 
square fluctuations (RMSF) of the Cα-atoms, the tilting angles 
of selected TM helices, the center-of-mass (CoM) distances 
between residue pairs of interest, and the formation/disruption 
of salt bridges. The orientational motions of TM1b (D79-N93) 
and TM6a (A308-L322) were evaluated based on the departure in 
the corresponding helical tilting angles from their original values. 
The stability of hDAT was assessed by evaluating the RMSD of the 
instantaneous conformers from the initial model, shown in Figure 
S1 in Supplementary Material. The RMSDs in eight different runs 
of 100 ns converged to an average value of 3.3 ± 0.6 Å. Departures 
from this average in some trajectories were mainly due to the high 
fluctuations of the EL2 loop. Figure S2 in Supplementary Material 
compares the RMSFs of Cα-atoms in different forms (apo, and 
DA-, AMPH-, and ORPH-bound) of hDAT. RMSD calculations 
repeated by excluding the EL2 loop yielded an average RMSD of 
2.0 ± 0.2 Å (Figure S1B in Supplementary Material).
experimental Material and Methods
Materials
HEK-293A cells (Invitrogen) were transfected with plasmid 
encoding DAT with an HA epitope inserted in the second EC 
loop (HA-DAT) (62) using Lipofectamine 2000 according to 
manufacturer’s protocol (Invitrogen). 3H-DA was from Perkin 
Elmer. ORPH and other chemicals were from Sigma.
DA Uptake Assays
Porcine aortic endothelial (PAE) cells with stable expression of 
hDAT were cultured as described previously (63). Cells were grown 
to confluence in 24-well dishes and treatments and assays were 
conducted in 37°C phosphate buffer saline (PBS) supplemented 
with 0.1 mM CaCl2, 1 mM MgCl2, and 10 mM glucose (PBS-CMG). 
Following 10 min uptake of 3H-DA, cells were washed twice with 
ice-cold PBS-CMG prior to lysis in 1% SDS and scintillation count-
ing. For experiments (shown in Figure 8A), ORPH and 3H-DA 
were added simultaneously following 10 min pre-treatment with 
10 μM cocaine as indicated. For kinetic assays (Figure 8B), ORPH 
was added 10 min prior to uptake.
Dopamine Transporter “HA Antibody Feeding” 
Endocytosis Assay
HEK cells with stable expression of HA-DAT were cultured on 
glass coverslips prior to HA antibody feeding assay (62). Cells 
were exposed to 1  μg/ml mouse anti-HA antibodies (HA11, 
Biolegend) in addition to treatment with vehicle (Veh), 100 μM 
AMPH, or 100 μM ORPH for 30 min prior to fixation in 4% 
paraformaldehyde. Cy3-conjugated donkey anti-mouse antibod-
ies (2 μg/ml) were added for 1 h to label cell surface HA-DAT. 
Following 5  min permeabilization with 0.1% Triton-x-100, 
Cy5-conjugated donkey anti-mouse antibodies (1 μg/ml) were 
added to visualize endocytosed HA-DAT. Z-stacks of x–y 
confocal images were acquired using a spinning disc confocal 
imaging system based on a Zeiss Axio Observer Z1 inverted 
fluorescence microscope (with 63× Plan Apo PH NA 1.4) 
equipped with a computer-controlled spherical aberration cor-
rection unit, Yokogawa CSU-X1, Photometrics Evolve 16-bit 
EMCCD camera, and environmental chamber and piezo stage 
controller and lasers (405, 445, 488, 515, 515, 561, and 640 nm), 
all controlled by SLIDEBOOK5 software (Intelligent Imaging 
Innovations, Inc.). Image acquisition settings were identical in 
all experiments. For quantitation, 3D images of eight random 
fields (each image containing typically 10–15 cells) from each 
condition were acquired through 561 nm (Cy3) and 640  nm 
(Cy5) channels. Quantitation of the amount of Cy3 (surface 
HA-DAT) and Cy5 (surface plus internalized HA-DAT) 
fluorescence was performed using the statistics module 
of SLIDEBOOK6. The background-subtracted 3D images 
were segmented using a minimal intensity of Cy3 or Cy5 
fluorescence as a low threshold to obtain segment Masks #1 
and #2. Mask #1 was subtracted from Mask #2 to obtain 
June 2015 | Volume 6 | Article 1345
Cheng et al. Drug modulation of hDAT
Frontiers in Neurology | www.frontiersin.org
Mask #3 corresponding to voxels containing only IC Cy5 
fluorescence (internalized HA11 complexes with HA-DAT). 
The ratios of integrated intensities of Mask #3 to Mask #1 
were calculated to determine the apparent extent of DAT 
internalization.
results
PMF studies identified eight repurposable 
Drugs for DaT, Two of Which are Further 
supported by 3D similarity
We first examined the largest interconnected graph in DrugBank 
v3.0 (45) to generate clusters of drugs and focused on a cluster 
that is predominantly composed of drugs listed to interact with 
DAT. Figure 2 displays those drugs (35 of them), grouped into six 
clusters based on their 3D-structural and chemical characteristics 
[determined using OpenEye OMEGA (42) and Shape]. Of these, 
eight are illicit or withdrawn, which reduced the FDA-approved 
set to 27.
As a second step, we considered the bipartite graph composed 
of 1,413 FDA-approved drugs and 1050 protein targets contained 
in DrugBank to obtain 74 potentially repurposable drugs. These 
were inferred from the top 10 predictions in 105 parallel PMF 
Figure 2 | Drugs/substrates listed in DrugBank v3.0 to interact 
with DaT, clustered in six groups based on their structural and 
chemical similarities. Membership of each cluster is listed, along with 
the structures (color-coded). Three substrates/drugs on which we focus, 
dopamine, amphetamine (AMPH), and cocaine, are highlighted in gray 
boxes on the right. The table contains, in addition to the DrugBank 
identifiers (first column) and names (second column; with asterisks 
indicating illicit or withdrawn drugs that have been removed from further 
analysis), the number of targets (third column) listed (in DrugBank) for each 
drug.
calculations (39, 41) repeated with different random/seed num-
bers. The resulting drugs are listed in Table S1 in Supplementary 
Material.
The combined set of 101 drugs was further subjected to 
agglomerative hierarchical clustering based on their latent (PMF-
derived) vectors. We repeated our analysis with three different 
distance metrics, Euclidian, cosine, and city-block. In each case, 
among the resulting clusters, those enriched in known DAT 
drugs were selected (see Figure S3 in Supplementary Material) 
and further examined to sort those repurposable drugs commonly 
identified with different metrics. This led to eight hits: fluoxetine, 
levomilnacipran, milnacipran, desvenlafaxine, ORPH, ephedrine, 
atomoxetine, and protriptyline.
Finally, these hits were further filtered based on their 3D 
fingerprint similarity to 122 drugs identified to be structurally 
and chemically similar to 35 original drugs, using a ComboScore 
threshold of 1.5 in OpenEye. This filtering procedure finally led 
to ephedrine and ORPH as two compounds that met both the 
PMF and 3D similarity criteria. ORPH, an anticholinergic agent 
and anti-PD drug (45), which yielded the highest score, has been 
selected for further tests/validation with the help of molecular 
computations and experimental assays. A schematic description 
of the overall procedure is provided in Figure 3.
Figure 3 | Flow diagram for the consolidation of repurposable drugs 
for DaT. A set of 101 drugs, composed of 27 FDA-approved drugs listed for 
DAT in DrugBank, and 74 repurposable drugs predicted by the PMF analysis 
(Table S1 in Supplementary Material), are grouped in clusters, based on their 
PMF latent vector similarities. Those clusters enriched in known drugs are 
examined to extract among repurposable drugs eight, consistently detected by 
different distance metrics (Euclidian, cosine, and city-block). Screening of these 
drugs against the subset of 122 drugs identified by OpenEye screening to be 
structurally and chemically similar to known drugs distinguishes two, ORPH 
and ephedrine (followed by desvenlafaxine, not shown). See the text for details. 
The highest scoring drug, ORPH, is selected for computational and 
experimental investigation.
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Docking analysis identifies a common high 
affinity Binding Pocket near the Primary 
substrate-Binding site s1
To identify the hDAT sites that potentially bind ligands or drugs, 
we performed docking simulations for DA, AMPH, ORPH, and 
cocaine. Computations performed in the presence and absence of 
Na+ and Cl- ions near S1 led to comparable ligand binding clusters 
and affinities, indicating that the bound Na+ and Cl- ions had a 
minor effect, if any, on ligand binding. This is presumably due to 
the fact that the ligand did not make direct contacts with these 
ions at the initial stage of binding. The most favorable binding site 
predicted by AutoDock was in all cases approximately halfway 
across the membrane in the EC vestibule (Figure 4A), equivalent 
to the nortriptyline binding site and close to the primary substrate 
binding site S1 (33). The binding poses of DA, AMPH, and cocaine 
were consistent with previous studies (13). Figures 4C,D show the 
coordination of ORPH, which displays similarities to that of Leu 
in LeuT (Figure 4C). For clarity, we divided the binding site into 
three subsites, a, b, and c (yellow circles). Subsite a is highly specific 
and presumably contributes to selective binding. In particular, 
F76 and D79 in hDAT (or their dDAT counterparts F43 and D46) 
coordinate the catecholamine DA binding, while N21 and G24 
(in LeuT) contribute to the binding of amino acids, such as Leu 
or Ala. Sites b and c are amphipathic and composed of highly 
conserved residues.
All four of the investigated drugs/substrates, DA, AMPH, 
ORPH, and cocaine, as well as nortriptyline, are positively charged. 
Their amine groups were usually involved in attractive electrostatic 
interactions with D79. Our simulations clearly show the critical 
role of D79 in stabilizing the binding to site S1 (Figures S4C–F in 
Supplementary Material). Note that a switch in salt bridge involving 
R85, from R85-D79 to R85-D476, accompanies the translocation 
of DA from S2 to S1. Release of D79 upon D79-R85 dissociation 
opens the way to the association of D79 with DA.
The s2 site at the upper ec Vestibule May  
serve as a Trap Binding the OrPh or cocaine 
Molecules that Diffuse from the ec region
Drugs modulate the function of DAT in different ways [for a recent 
review see Ref. (2)]: some, such as cocaine, are not transportable; 
they inhibit substrate transport by stabilizing a certain conforma-
tion (e.g., OF state) and thus arresting the transport cycle; whereas 
others, such as AMPH, compete with DA; they may be transported 
as a substrate and stimulate the efflux of IC DA. Currently, there 
Figure 4 | substrate/drug binding to hDaT outward-facing open 
(OFo) state. (a) The most favorable binding site identified for DA (magenta 
stick), AMPH (yellow stick), ORPH (dark blue stick), and cocaine (orange 
stick). The site is broadly equivalent to the nortriptyline binding site resolved in 
dDAT, in the close vicinity of the substrate-binding site S1. (B) Alternative 
cocaine binding sites identified by AutoDock. Three poses representative of 
three clusters are shown, with docking energies varying from -6.6 (orange) to 
-5.5 (yellow), to -4.8 kcal/mol (green). These binding sites span the entire EC 
vestibule from the entrance (near S2) to the S1 site. (c) Comparison of the 
binding geometry of ORPH in hDAT, and that of Leu in LeuT. All residues that 
are within 3 Å distance from ORPH (based on atom-atom contacts) are listed 
along with their LeuT counterparts (written as hDAT/LeuT residues). (D) The 
residues coordinating the binding of ORPH at site S1 are distributed in three 
subsites, labeled a–c. More detailed view of the coordination geometry of 
ORPH near S1, displayed from two different perspectives. ORPH is shown in 
surface representation.
Figure 5 | Dopamine binding to site s1 prompts the closure of ec 
gate and dopamine-bound hDaT resembles leu-bound leuT.  
(a) Substrate binding pocket before dopamine binding, typical of the 
outward-facing open conformation; (B) same pocket after dopamine (vDW 
format) binding. Isomerization of F320 (purple) brings its aromatic side chain 
on top of dopamine. Close association of Y156-F320 and salt bridging of 
R85-D476 designate the closure of the EC gates, indicating hDAT in its 
outward-facing closed state; and (c) crystal structure of LeuT with Leu 
bound to the S1 site (PDB: 2A65), in which the homologous EC gate 
residues orient in a similar pose to that shown in (B). Snapshot in (B) is 
taken from 100 ns in run DA-bound-1.
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is no direct evidence in the literature whether ORPH binds DAT 
or not, or whether it is transportable or not. The above docking 
simulations show that it can bind and insert into the substrate-
binding site S1 of hDAT, suggesting a competitive binding with 
other DAT substrates and drugs. The same simulations also 
showed, on the other hand, while the best docked models for DA 
and AMPH were exclusively confined to the close vicinity of site 
S1, those predicted for cocaine and ORPH varied over a broader 
range spanning an extended region between the EC vestibule and 
the site S1, including the vicinity of site S2. Figure 4B illustrates 
the alternative conformers predicted for cocaine.
As a further test, we explored the behavior of cocaine and 
ORPH molecules originally located in the EC region. MD simu-
lations of binding from the EC region revealed the tendency 
of cocaine and ORPH binding to diffuse and settle near S2 
[Figure S5 in Supplementary Material; secondary binding site 
proposed for Leu binding to LeuT (56)]. Therefore, while the 
S1 site of the original OFo structure is a high-affinity site, these 
relatively large ligands got trapped near S2. Further transloca-
tion to S1 was apparently hindered by tight interactions near 
S2. Simulations for DA, on the other hand, showed that DA 
proceeded to S1 after transiently binding S2 (Figure S4 in 
Supplementary Material). The inability of these two compounds 
to penetrate deeper into the binding pocket could affect, if not 
impair, the changes in the structure of the transporter that 
would otherwise be triggered upon ligand binding onto the 
primary site S1. This possibility is explored next by extensive 
MD simulations.
Da and aMPh Trigger the reconfiguration of 
hDaT upon Binding, from the OFo to OFc* 
substate Predisposed to substrate 
Translocation; OrPh arrests it in the OFo* state
To further explore whether binding is succeeded by transloca-
tion, we constructed four MD simulation systems: one control 
without substrate/drug and three in the presence of DA, AMPH, 
or ORPH, docked to the S1 site of hDAT in the OFo conformation 
(Figure 1A). For each system, two independent 100  ns conven-
tional MD runs were carried out to verify the reproducibility of 
the results.
Binding of either DA or AMPH to the S1 site was consistently 
observed to trigger significant conformational changes in the EC 
vestibule, which led to the OFc* state. The OFo and OFc* states 
were distinguished by three major criteria (24): opening/closure 
of the outer and inner EC gates, inter-helix packing, and hydration 
pattern of both the EC and IC vestibules. First, the EC gates were 
observed to close within tens of nanoseconds (Figures 5 and 6; 
Figures S6 and S7 in Supplementary Material). In particular, the 
salt-bridge of R85-D476 that serves as the outer EC gate spontane-
ously formed after DA- (Figure 5) or AMPH-binding (Figure 6); 
and the F320 side chain underwent a rotational isomerization, 
from χ1 =  -80 ±  15° to -170 ±  15° (Figure  6B; Figure S7B in 
Supplementary Material), which enabled its association with 
Y156, forming the inner EC gate that further sealed the substrate 
Figure 6 | aMPh binding to site s1 facilitates hDaT structural 
transition from outward-facing open (OFo) to outward-facing  
closed (OFc*) state. Time evolutions of (a) N–O distance of R85-D476. 
Salt-bridge was formed around 20 ns; (B) χ1 of F320. F320 flipped on  
top of dopamine as χ1 stably changed from -80 ± 15° to 170 ± 15°  
around 35 ns; (c) CoM distances of EC-exposed TM segments TM6a–TM10 
(green) and TM1b–TM10 (blue). (D) In the OFc* state, side view of the 
binding site for AMPH (yellow vDW) was dehydrated and occluded  
to both EC and IC region. Two hydrophobic layers F320-V152 (upper)  
and F76-F326-V328 (lower) prevent water penetration from both  
sides. Water molecules in the EC and IC vestibules are shown in  
CPK format with semi-transparent cyan. Results were taken from  
run AMPH-bound-1. Transition from OFo to OFc* was also observed in  
AMPH-bound-2.
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from the EC environment. The closure of these two EC-gates R85-
D476 (R30-D404 in LeuT) and Y156-F320 (Y108-F253 in LeuT) 
upon the binding of DA or AMPH (Figure S6 in Supplementary 
Material) to the S1 site is in striking similarity to the sequence of 
events observed in our previous investigation of Ala binding to 
LeuT (25).
Second, the binding of DA or AMPH prompted an inward 
tilting of TM1b (10–15°) and TM6a (2–10°) segments toward the 
center of the EC vestibule (Figures  6C and 7; and Figure S7C 
in Supplementary Material). The inter-helical packing geometry 
of the EC vestibule reached values typical of OFc* state within 
100 ns MD simulations (Figures 6C; Figure S7C in Supplementary 
Material). Notably, the DA- or AMPH-bound hDAT resembles 
significantly the Leu-bound LeuT in the OFc* state (Figures 5 and 
7), which is predisposed to substrate translocation and release as 
confirmed in earlier work (24, 25).
Third, in contrast to the OFo state where there is a continuous 
water occupancy in the EC vestibule, in the OFc* state, the site S1 
is minimally hydrated: it contains only 3–5 water molecules that 
assist in coordinating one of the two co-transported sodium ions 
(designated as Na2) and the substrate (Figure 6D; Figure S7D in 
Supplementary Material). Two layers of hydrophobic interactions, 
one on each side of the binding site, seclude the binding site from 
water penetration from either the EC and IC region: F320-V152 
(upper) and F76-F326-V328 (lower). Overall, similar residues 
coordinate the binding of DA or AMPH in the OFc* state. These 
include F76 and D79 on TM1; S149, V152, G153, and Y156 on 
TM3; F320, S321, F326, and V328 on TM6; and S422 and G426 
on TM10 (Figures 7A,B).
While DA- and AMPH-bound hDAT spontaneously proceeded 
from OFo to OFc*, evidenced by these three distinctive properties, a 
completely different behavior was exhibited by ORPH-bound hDAT. 
ORPH was coordinated by W84 (TM1b) and F155 (TM3) in addition 
to other residues that also coordinate DA and AMPH (Figure 7). A 
major difference was that in contrast to DA and AMPH, no significant 
closure of the EC vestibule was observed in two independent simula-
tions of ORPH-bound hDAT (Figures S6 and S7 in Supplementary 
Material); essentially hDAT maintained its OFo conformation, with 
continuous water occupancy at the EC vestibule. The EC-exposed 
TM6a displayed negligible change in its orientation and the TM10 
segment underwent a ~5° outward tilting to even further enlarge 
the EC vestibule rather than contracting it, presumably to accom-
modate the larger size ORPH. Notably, TM1b (exposed to the EC 
region) underwent a ~5° inward tilting, although this reorientation 
remained ~5° smaller compared to that observed in DA-bound or 
AMPH-bound hDAT. ORPH wedged between F320 (TM6a) and 
Y156 (TM3). Due to its bulky size, F320 was not able to flip over the 
top of ORPH to seclude it from the EC region, as observed in AMPH-
bound and DA-bound hDAT (Figures 7A–C), but remained on the 
side; the F320-Y156 distance maintained its typical value (12 ± 1.0 Å) 
in the OFo conformation, which is ~4 Å larger than that observed in 
the OFc* state (Figure S6 in Supplementary Material).
Given that the DAT conformational changes conducive to the 
translocation of substrate could not occur in the ORPH-bound 
Figure 7 | specific interactions of hDaT with Da (left), aMPh (middle), 
and OrPh (right) and accompanying structural changes in hDaT. 
Binding of either DA or AMPH leads to hDAT reconfiguration from the OFo to 
OFc* state; whereas binding of ORPH has no such effect, and the OFo 
conformation is further stabilized. (a–c) Illustrate the coordination geometry of 
(a) DA, (B) AMPH, and (c) ORPH. Alignment of the initial OFo hDAT (orange) 
with the MD-relaxed hDAT (yellow) in the presence of (D) DA; (e) AMPH; and 
(F) ORPH. For clarity, only TM1, TM6, and TM10 helices are highlighted in 
cartoon and MD-relaxed structures are shown in white ribbon. Results are 
taken from the last 100 ns MD simulations in each case.
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transporter, we propose that like cocaine, ORPH is not likely to 
be transported. This is due to both its bulky size which hinders the 
closure of the EC gating pairs D476-R85 and F320-Y156 (compare 
in Figures 7D–F) and impedes the concerted inward tilting of the 
EC-exposed TM helices. Our conjecture is supported by docking 
simulations of ORPH, cocaine, DA, and AMPH conducted with 
the hDAT in the OFc* conformation, obtained by the present MD 
simulations. No ORPH or cocaine molecule was found to bind the 
EC vestibule in the OFc* state, while DA and AMPH exhibited 
significant increase of binding affinity to the S1 site (Table S2 in 
Supplementary Material). Furthermore, neither DA nor AMPH 
were able to bind the S2 site in the hDAT OFc* conformation, 
suggesting that the site S2 (56) is a transient substrate-binding 
site accessible when hDAT is in the OFo state only (see Figure S4 
in Supplementary Material).
Simulations initiated by placing the ORPH and cocaine more 
than 20  Å away from the site S1 (Figure S5 in Supplementary 
Material) also showed that the pair F320-Y156 maintained its 
typical distance of 13.5 ± 0.5 Å of the OFo conformation over 
the entire simulations. The EC salt-bridge of R85-D476 intermit-
tently formed in ORPH-bound OFo, preventing the ORPH from 
penetrating further toward S1. The formation of this salt bridge 
was not sufficient, however, for the closure of the EC vestibule. 
Therefore, the transporter remained arrested in OFo* state.
substrate Transport experiments confirm  
OrPh as competitive inhibitor
To determine whether ORPH affects DAT function, we measured 
uptake of 3H-DA by PAE cells that express the human DAT. 
ORPH caused a dose dependent decrease in DA uptake with an 
IC50 of ~10 μM (Figure 8A). Cocaine, a competitive inhibitor of 
DA transport, reduces inhibition by other competitive inhibitors 
but not non-competitive (allosteric) inhibitors. In the presence of 
10 μM cocaine, the IC50 of ORPH increased more than 20-fold, 
suggesting that ORPH, like cocaine, is a competitive DAT inhibitor 
(Figure 8A). While DAT inhibitors like cocaine inhibit DAT func-
tion by blocking substrate binding, the DAT substrate AMPH can 
also modulate both the affinity and the capacity for DA transport 
by engaging IC signaling pathways that alter the expression of the 
transporter at the cell surface (10, 64). To examine the effect of 
ORPH on DAT substrate affinity and capacity, we performed 3H-
DA uptake experiments in the presence of 20 μM ORPH. ORPH 
decreased the affinity of DA for the transporter by nearly 10-fold, 
with little change in transport capacity (Figure 8B). These results 
Figure 8 | (a) Competitive inhibitory properties of ORPH confirmed by 
experiments. Uptake of 3H-DA by PAE cells expressing human DAT was 
measured in the presence of the indicated concentration of orphenadrine 
(ORPH) alone or following 10  min pre-treatment with 10 μM cocaine. 
Means of three replicates ± SEM were plotted as a percentage of the 
uptake remaining from lowest ORPH concentration in respective group 
(either alone or with cocaine). ORPH concentration for 50% inhibition of 
dopamine uptake (IC50) was calculated. (B) Uptake of the indicated 
concentrations of 3H-DA by PAE cells expressing hDAT was measured in 
the presence of no drug (control) or following 10  min pre-treatment with 
20 μM ORPH. Mean ± SEM of three replicates were plotted and Michaelis–
Menten non-linear regression analysis was performed, providing transporter 
dopamine affinity (Km) and capacity (Vmax) for each condition. (c) HEK cells 
expressing HA-DAT were treated for 30 min with water vehicle (Veh), 
100 μM amphetamine (AMPH), or 100 μM orphenadrine (ORPH) and were 
subjected to the “HA antibody feeding” assay as described in section 
“Materials and Methods” prior to imaging by confocal fluorescence 
microscopy. Surface transporters appear red and green (yellow), while 
intracellular transporters appear in green only. Examples of endocytosed 
HA-DAT (green) are circled. Representative images from three replicates are 
shown. The fold change in the ratio of IC:surface transporters was 
determined by quantitative analysis of surface and IC signals as described 
in section “Materials and Methods.” Values are the means of eight 
determinations and error bars are standard deviations. Significant difference 
from vehicle (*p < 0.05) was determined by one-way ANOVA followed by 
the Tukey post-test for multiple comparisons.
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suggest that ORPH inhibits DA transport by interfering with DA 
binding as opposed to downregulating the plasma membrane 
transporter.
To assess more directly whether ORPH affects the plasma mem-
brane expression of the DAT, we assessed transporter internalization 
using confocal fluorescence microscopy. DAT containing an HA 
epitope inserted in the second EC loop (HA-DAT) will carry bound 
HA antibodies from the plasma membrane to endosomes, allowing 
efficient visualization and quantitation of endocytosis (62). HEK 
cells expressing HA-DAT were incubated for 30 min in the presence 
of anti-HA antibodies along with vehicle, AMPH, or ORPH treat-
ment (Figure 8C). Following fixation, cell surface HA-DAT was 
detected by incubation with Cy3-conjugated secondary antibodies 
(red) prior to permeabilization, and endocytosed transporter was 
detected by incubation with Cy5-conjugated secondary antibod-
ies (green) after permeabilization. HA-DAT accumulated in IC 
compartments following treatment with AMPH, while cells treated 
with ORPH resembled the control condition with predominantly 
plasma membrane transporters. All together, these results indicate 
that the actions of ORPH are similar to that of the DAT competitive 
inhibitor cocaine, as opposed to the DAT substrate AMPH.
Discussion
The major findings in this study may be summarized as follows: 
(i) the identification and validation of ORPH as a repurposable 
drug for DAT, supported by both computations and experiments, 
(ii) the elucidation of the mechanisms of interaction of hDAT with 
substrates (DA and AMPH) and blockers (ORPH and cocaine), 
pointing to the critical role of selected residues such as D79, the 
salt-bridge R85-D476, and aromatic pairs F320-Y156 serving as 
outer and inner EC gates, respectively, (iii) the demonstration of 
the contrast between the conformational changes of hDAT trig-
gered by these two groups of compounds, consistent with their 
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distinctive modulation on DAT function: the former two spontane-
ously prompt structural transitions toward facilitating DA/AMPH 
translocation, the latter two arrest hDAT in the outward-facing 
open (OFo*) state, and (iv) the primary binding site S1 is a high 
affinity site for all four examined compounds. However, access 
to this site from the EC region varies. While the DA and AMPH 
unambiguously locate this site, cocaine/ORPH may bind multiple 
sites in the EC vestibule. In particular, the site S2 emerges as a first 
stop for binding EC substrates and ORPH and cocaine exhibit 
a tendency to get trapped therein due to their larger sizes and 
tighter interactions.
Previous structure-based studies of DAT-substrate/drug interac-
tions used LeuT, which shares 22% sequence identity with hDAT, 
as template. Despite the low sequence similarity, the conservation 
of the fold and local packing geometry near the substrate-binding 
site permitted to gain insights into DAT conformational changes 
involved in cocaine binding and DA translocation (13, 18–20, 
65–69). Here, for the first time, we used as template, the recently 
resolved dDAT structure (33), which shares >50% sequence identity 
with hDAT, and we modeled the EL2 loop unresolved in the fruit 
fly orthologs using as constraint data from previous cross-linking 
studies (16, 47) (Figure 1). The new model yielded many results 
corroborating previous findings, highlighting the structural and 
functional features conserved among LeuT fold family members 
in support of the use of LeuT as a template in earlier studies. For 
example, the R30- D404 gate of LeuT is replaced by R85-D476, or 
Y108-F253 of LeuT is replaced by Y156-F320 in hDAT. Recent work 
showed that DAT R85D mutant had a complete loss of function, 
which was restored by the compensating mutation R85D/D476R 
(68). In addition to such generic features, this study provides time-
resolved full-atomic data and functional information specific to 
hDAT in the presence of DA, AMPH, cocaine, and ORPH. Yet, 
we note that due to the flexibility of the modeled EL2 loop, the 
putative Zn2+ binding pocket may be destabilized in the simulations. 
Further refinement of the EL2 loop using more structure constraints 
gleaned from experimental studies (16) may help.
Our docking simulations suggest that the most favorable bind-
ing site for cocaine and ORPH resides in the close proximity of 
the primary binding site S1, where it may compete with substrate 
(Figure 4A). These results are consistent with previous studies 
(13, 70) as well as the binding of antidepressant nortriptyline onto 
dDAT (33). In contrast, tricyclic antidepressants desipramine and 
clomipramine were crystallographically found to bind LeuT non-
competitively at a site equivalent to site S2 (22, 71). A previous 
computational study of hDAT (20), modeled based on LeuT, 
proposed an allosteric triggering of DA release from S1 through 
the binding of another DA to S2. While the existence of S2 [as either 
a high affinity (72) or low-affinity site (23) for substrate binding] is 
well-established in LeuT and other NSS family members, such as 
DAT, SERT, and NET (71, 73, 74), crystal structural and functional 
analyses cast doubts on its relevance to the allosteric regulation of 
substrate release (23). The present MD simulations suggest that site 
S2 may be a first stop for the recognition and transient binding of 
DA from the EC medium (Figure S4 in Supplementary Material), 
and it may act as a trap precluding the effective penetration of the 
blockers, ORPH and cocaine, into the inner EC vestibule (Figure S5 
in Supplementary Material). ORPH, like cocaine, may be involved 
in multiple binding pauses/interactions in the EC vestibule, sup-
porting the view that inhibition can occur through multiple bind-
ing mechanisms (73). The present docking studies as well as MD 
simulations clearly demonstrate that the mechanism of inhibition 
by ORPH is the stabilization of the OFo* conformation (Figure 7). 
Furthermore, this study suggests that the ligand binding affinity is 
state-dependent (see Table S2 in Supplementary Material).
In our simulations, D79 was noted to play an important role 
in coordinating the ligand binding to site S1 (Figures 4 and 7). 
This aspartate is conserved among neurotransmitter transporters, 
such as DAT, SERT, and human desipramine-sensitive NET that 
share the LeuT fold; it facilitates the recognition of catecholamines 
(compounds such as DA, serotonin, epinephrine, and norepineph-
rine, which contain a benzene group with two attached hydroxyls). 
Substitution of the counterpart D75 in hNET by alanine led to an 
almost complete loss of NE uptake (75). Likewise, mutations of 
D79 to alanine, glycine, or glutamate significantly reduced DA 
uptake and the affinity for tritium-labeled cocaine analog (75). The 
fact that D79E also reduces DA uptake suggests that not only the 
electrostatic potential but also the size of amino acid at position 
79 is important in mediating DA translocation. The reduced DA 
uptake in these mutants was attributed to the reduced ability to 
recognize DA or to the inability of the transporter to efficiently 
transport it after recognition (75).
Comparison of the effect of ORPH on hDAT structural dynam-
ics to that of the substrates DA and AMPH reveals striking differ-
ences. DA and AMPH practically exhibit the same effect (compare 
Figure  6 for AMPH and Figure S7 in Supplementary Material 
for DA; or the middle two panels in Figure S6 in Supplementary 
Material; or the panels for DA and AMPH in Figure 7). Like DA, 
AMPH can translocate from the EC to the IC region mediated by 
DAT (76). In addition, AMPH may induce non-vesicular release 
of DA and trigger the subsequent efflux of DA back to EC region 
(76), thus increasing the EC DA levels in motivational and reward 
areas of the brain. Currently, it remains elusive how AMPH trig-
gers non-vesicular release of DA and then the efflux of DA. It has 
been proposed that AMPH causes DAT-mediated DA efflux via 
two independent mechanisms: (76) one slow process consistent 
with transporter mechanism and the other rapid process through 
channel-like mode of DAT. In this study, we observed that binding 
the EC AMPH led to hDAT structural transition from OFo to OFc* 
state, which broadly resembles that induced by the binding of EC 
DA. We suggest that binding of the EC AMPH may not directly 
trigger the DA efflux. Further studies investigating the effect of 
AMPH binding to the IC-exposed domains of hDAT, including 
in particular the N-terminal segment, are needed to elucidate the 
molecular basis of DAT efflux elicited by AMPH.
conclusion
In this study, we utilized QSP and computational biology methods 
and molecular biology experiments to study the structure- and 
time-dependent mechanisms of interactions of known (cocaine, 
DA, and AMPH) and predicted (ORPH) drugs/substrates with 
human DAT (hDAT). First, by taking into consideration both 
structural similarities (compared with known agonists/antago-
nists) and functional patterns (from drug–protein interacting data, 
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analyzed by machine learning method), we identified ORPH as 
a repurposable drug that might bind DAT and alter/inhibit its 
activity. Examination of the binding properties of ORPH, AMPH, 
DA, and cocaine, revealed two distinct modulation effects. While 
ORPH like cocaine inhibits hDAT function by stabilizing the OFo* 
state (or preventing the closure of the EC vestibule) and thereby 
arresting the transport cycle, binding of AMPH or DA triggered 
cooperative conformational changes, including TM helices rear-
rangements, conducive to substrate transport.
Computational prediction of repurposable drugs became an 
important research goal in recent years, after the pioneering work 
of the Schoichet laboratory (35). The method we introduced to 
this aim is based on the target similarities between drugs (40, 41). 
While such machine-learning algorithms provide new hypoth-
eses, it is essential to thoroughly examine them by additional 
molecular simulations and by experiments/assays to test and 
establish the effects of the repurposable drugs. Here, statistical 
analyses and chemical similarity-based screens for selecting from 
hits (Figures  2 and 3), docking computations (Figure  4), MD 
simulations (Figures 5–7), DA-uptake, and DAT internalization 
assays (Figure 8) showed the ability of ORPH to competitively 
bind DAT, prevent closure of EC gates, and cause a reduction in 
DA uptake and in DAT endocytosis.
Design of transporter blockers is the most commonly applied 
strategy for antidepressant therapy (38), and notable advances 
are currently made in search for novel ligands that allosterically 
modulate DAT function (77). In principle, from pharmacological 
point of view, it is desirable to have a compound that prevents the 
binding of cocaine, while retaining the DA-transport function 
of DAT. Our experiments showed a decrease in DA reuptake in 
the presence of ORPH, without significant downregulation in the 
transport capacity of the transporter. Further studies with ORPH 
and other repurposable drugs (e.g., ephedrine, desvenlafaxine) could 
be worth pursuing to identify compounds that optimally interfere 
with cocaine binding while leaving DA binding and transport prop-
erties unaffected. Furthermore, design of drugs that can potentially 
perturb hDAT interactions with regulatory proteins (78) or altering 
hDAT trafficking (79) might be useful in developing new approaches 
for regulating hDAT function and DA neurotransmission in vivo.
author note
After acceptance of our manuscript, the crystal structures of dDAT 
resolved in the presence of cocaine, dopamine, and amphetamine 
has been published (80). Notably, the binding poses of these drugs 
as well as their binding sites on dDAT show close similarities to 
those predicted by our simulations for substrate/drug bound hDAT 
in the OFo state (Figure 4A). Our MD simulations further revealed 
that binding of AMPH or dopamine to the site S1 promotes the 
closure of the outward-facing hDAT and stabilizes the OFc* state 
(Figures 5 and 6).
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